Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Should You Buy The New York Times Company (NYT)?

Is The New York Times Company (NYSE:NYT) undervalued? Prominent investors are in a bullish mood. The number of bullish hedge fund positions moved up by 1 recently.

To the average investor, there are plenty of indicators investors can use to track their holdings. Two of the most under-the-radar are hedge fund and insider trading movement. At Insider Monkey, our research analyses have shown that, historically, those who follow the best picks of the top investment managers can outperform the broader indices by a healthy amount (see just how much).

The New York Times Company (NYSE:NYT)

Just as integral, optimistic insider trading sentiment is another way to parse down the financial markets. As the old adage goes: there are a variety of incentives for an executive to sell shares of his or her company, but only one, very obvious reason why they would behave bullishly. Many empirical studies have demonstrated the impressive potential of this method if shareholders know what to do (learn more here).

With these “truths” under our belt, we’re going to take a gander at the latest action surrounding The New York Times Company (NYSE:NYT).

How are hedge funds trading The New York Times Company (NYSE:NYT)?

At year’s end, a total of 14 of the hedge funds we track were bullish in this stock, a change of 8% from the third quarter. With hedgies’ positions undergoing their usual ebb and flow, there exists an “upper tier” of noteworthy hedge fund managers who were boosting their stakes significantly.

When looking at the hedgies we track, Irving Kahn’s Kahn Brothers had the largest position in The New York Times Company (NYSE:NYT), worth close to $41 million, accounting for 7.1% of its total 13F portfolio. On Kahn Brothers’s heels is Ken Griffin of Citadel Investment Group, with a $35 million position; the fund has 0.1% of its 13F portfolio invested in the stock. Other hedge funds with similar optimism include Larry Foley and Paul Farrell’s Bronson Point Partners, Chuck Royce’s Royce & Associates and Glenn Russell Dubin’s Highbridge Capital Management.

With a general bullishness amongst the heavyweights, some big names have been driving this bullishness. Bronson Point Partners, managed by Larry Foley and Paul Farrell, assembled the most outsized position in The New York Times Company (NYSE:NYT). Bronson Point Partners had 12 million invested in the company at the end of the quarter. Glenn Russell Dubin’s Highbridge Capital Management also made a $4 million investment in the stock during the quarter. The other funds with new positions in the stock are James H. Litinsk’s JHL Capital Group and Steven Cohen’s SAC Capital Advisors.

Insider trading activity in The New York Times Company (NYSE:NYT)

Insider trading activity, especially when it’s bullish, is most useful when the company in question has experienced transactions within the past six months. Over the last six-month time frame, The New York Times Company (NYSE:NYT) has seen 1 unique insiders purchasing, and zero insider sales (see the details of insider trades here).

Company Name # of Hedge Funds # of Insiders Buying # of Insiders Selling
The McClatchy Company (NYSE:MNI) 11 0 1
Journal Communications, Inc. (NYSE:JRN) 11 0 2
Gannett Co., Inc. (NYSE:GCI) 21 0 8
The E.W. Scripps Company (NYSE:SSP) 15 0 7

With the results shown by our time-tested strategies, everyday investors should always monitor hedge fund and insider trading activity, and The New York Times Company (NYSE:NYT) is an important part of this process.

Click here to learn more about Insider Monkey’s Hedge Fund Newsletter

Insider Monkey’s small-cap strategy returned 37% between September 2012 and March 2013 versus 12.9% for the S&P 500 index. Try it now by clicking the link above.

Related tickers: The McClatchy Company (NYSE:MNI), Journal Communications, Inc. (NYSE:JRN), Gannett Co., Inc. (NYSE:GCI), The E.W. Scripps Company (NYSE:SSP)

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!